Foghorn Therapeutics Inc. (FHTX) Stock Price & Analysis
Foghorn Therapeutics Inc. (FHTX) fell 4.34% to USD 4.85 as of July 25, 2026 at 06:30 UTC, according to Nexqual real-time market data.
FHTX last closed at USD 5.07; the session ranged USD 4.76–5.08 on volume of 122,070 shares. Market capitalization is $284.76M, with a 52-week range of USD 3.27–6.95 (NGM). Source: Nexqual, July 25, 2026 at 06:30 UTC.
Key Statistics (as of July 25, 2026 at 06:30 UTC)
| Price | USD 4.85 |
|---|---|
| Change | ▼ 4.34% (down) |
| Previous Close | USD 5.07 |
| Open | USD 5.03 |
| Day Range | USD 4.76 – 5.08 |
| 52-Week Range | USD 3.27 – 6.95 |
| Volume | 122,070 shares |
| Market Cap | $284.76M |
| Exchange | NGM |
Technical Analysis (FHTX)
Nexqual's technical model rates FHTX "BUY" based on 4 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 06:30 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 48.45 (neutral) |
| vs SMA50 | Above (USD 4.51) |
| MACD | 0.15 (positive) |
Analyst Ratings (FHTX)
Wall Street analysts rate FHTX "Strong Buy" based on 9 analysts, with a mean price target of USD 11.44 (range USD 9–14), per Nexqual as of July 25, 2026 at 06:30 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 11.44 |
| High Target | USD 14 |
| Low Target | USD 9 |
| Buy / Hold / Sell | 10 / 0 / 0 |
Earnings (FHTX)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD -0.23 |
| Revenue Estimate | $7.93M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.29 vs est -0.31 ▲ beat |
| 2025-12-31 | USD -0.37 vs est -0.26 ▼ miss |
| 2025-09-30 | USD -0.25 vs est -0.3 ▲ beat |
| 2025-06-30 | USD -0.28 vs est -0.32 ▲ beat |
Source: Nexqual, July 25, 2026 at 06:30 UTC.
Financials & Fundamentals (FHTX)
| Total Revenue | $28.22M |
|---|---|
| Revenue Growth (YoY) | -45.10% |
| Gross Margin | -190.88% |
| Operating Margin | -660.33% |
| Profit Margin | -266.88% |
| Current Ratio | 2.92 |
| Total Cash | $183.63M |
| Total Debt | $41.99M |
| Free Cash Flow | $-36.93M |
Source: Nexqual, July 25, 2026 at 06:30 UTC.
Financial Health Score (FHTX)
Nexqual rates Foghorn Therapeutics Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 06:30 UTC.
| Growth | Strong — Revenue +37% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $184M cash vs $42M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$37M, burning cash |
| Efficiency | Mixed — No data |
Ownership (FHTX)
| Insider Ownership | +14.30% |
|---|---|
| Institutional Ownership | +76.75% |
| Shares Outstanding | 58.71M |
| Float | 27.41M |
| Short % of Float | +4.80% |
Source: Nexqual, July 25, 2026 at 06:30 UTC.
Leadership (FHTX)
Foghorn Therapeutics Inc. is led by Adrian H. B. Gottschalk (age 49), President, CEO & Director, per Nexqual as of July 25, 2026 at 06:30 UTC.
| President, CEO & Director | Adrian H. B. Gottschalk (age 49) |
|---|---|
| Founder & Independent Chairman of the Board | Douglas G. Cole (age 65) |
| Chief Scientific Officer | Steven F. Bellon (age 60) |
| Chief Financial Officer | Ryan D. Maynard (age 56) |
| Vice President of Corporate Development | Saurabh Sewak |
Major Backers & Investors (FHTX)
Notable institutional backers of Foghorn Therapeutics Inc. include Flagship Pioneering LLC, FMR, LLC, BVF Inc., according to Nexqual as of July 25, 2026 at 06:30 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Flagship Pioneering LLC | 21.59% |
| FMR, LLC | 10.3% |
| BVF Inc. | 9.95% |
| Deerfield Management Company, L.P | 7.48% |
| Fidelity | 5.96% |
| Raymond James Financial, Inc. | 4.43% |
| Euclidean Capital Llc | 2.68% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 5.71% |
| Vanguard Group | 5.03% |
| Geode Capital | 1.44% |
Source: Nexqual, July 25, 2026 at 06:30 UTC.
From Foghorn Therapeutics Inc.'s Latest SEC 10-K Filing (filed 2026-03-11)
Key Strengths & Strategy (as disclosed to the SEC)
- Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States.
- The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.
- It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome.
- The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PRLD | Prelude Therapeutics Incorporat | USD 3.83 | ▼ 2.42% |
| CCCC | C4 Therapeutics, Inc. | USD 3.4 | ▼ 9.09% |
| STTK | Shattuck Labs, Inc. | USD 7.43 | ▲ 5.84% |
| CGEM | Cullinan Therapeutics, Inc. | USD 17.1 | ▼ 3.12% |
| KYMR | Kymera Therapeutics, Inc. | USD 110.57 | ▲ 0.21% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 06:30 UTC. This page is informational and not investment advice.